Global ambition to eliminate viral hepatitis 

Globally, an estimated 71 million people have chronic hepatitis C virus (HCV) infection, and the number is increasing, despite the existence of curative treatments.1,2

Approximately 14 million (1 in 50) Europeans are chronically infected with HCV – about 20% of the global total.3 

HCV is transferred through contact with infected blood and is commonly transmitted through:

• Injectable drug use
• Inadequate sterilisation of medical equipment
• Transfusion of unscreened blood and blood products.1

People who inject drugs are at increased risk of acquiring HCV due to sharing syringes, needles and other injecting equipment.1

Estimates suggest that in 2015 there were 1.75 million new HCV infections worldwide and the number of deaths from viral hepatitis infection is increasing.1,4

Figure 1: Global burden of disease in 20165

In 2016, the World Health Organization (WHO) set the goal

of eliminating viral hepatitis as a major public health threat by 20302

Key milestones

2014: a new class of medicines, the direct acting antivirals (DAAs) became available as a cure for patients living with chronic HCV infection, achieving cure rates of over 90%.6

The introduction of DAAs has contributed to reductions in:7-10

HCV prevalence

Disease progression


May 2016: the WHO recognised the opportunity of the new DAAs and released its first global strategy on viral hepatitis.2 It called for the elimination of viral hepatitis as a major public health threat by 2030.

The strategy provides a vision of a world where viral hepatitis transmission is halted and everyone living with viral hepatitis has access to safe, affordable and effective care and treatment.2  

Specifically, the strategy defines elimination as:2

An 80% reduction in new HCV infections and

A 65% reduction in HCV mortality

Ambition is not enough: Your role in supporting elimination

Elimination is now more possible than ever.

Currently only 12 countries are on track to achieve the goal and a further 18 which are working towards elimination. This is based on estimates from a global registry, the Polaris Observatory, which provides epidemiological data, modelling tools, and decision analytics in viral hepatitis to support the WHO elimination goal.11

Progress is being made, but there is still more to do. Each and every person who is involved in the care for people living with HCV has a role to play: 


  • If you’re a healthcare professional, you’re instrumental in implementing screening and linkage to care programmes, or simplifying treatment pathways for those with difficulty accessing care
  • If you’re a policy maker or advocate, you are key to support active monitoring on the progress of existing national plans or voice the need for a dedicated national plan in some countries
  • If you work with people living with HCV, help raise awareness of the disease and drive testing in your community
  • If you think you or someone you know may have HCV, speak to your doctor and get tested
  • Or if you work with people who are at high risk of contracting HCV or have difficulty accessing care (e.g. people who use drugs), help them get tested or understand the benefits of HCV treatment and work with healthcare professionals to bring treatment to those living with HCV.

Elimination will not happen unless we all work together – everyone has a role to play and every action helps to move towards the WHO goal.

Gilead actively supports the efforts of governments and partners with professional organisations, patient advocacy groups, payers and healthcare professionals around the world who have declared their intention and commitment to work towards the WHO goal of elimination of viral hepatitis by 2030.

Opinion poll

How do you view your role in helping achieve the WHO goal to eliminate Hepatitis C by 2030?
Loading ... Loading ...

Projects: Elimination is happening here



Information on Australia’s approach to elimination of HCV



On course to being the first country worldwide to eliminate HCV



HCV elimination in resource-limited communities

DAA, direct-acting antiviral; HCV, hepatitis C virus; HIV, human immunodeficiency virus


While this information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact the accuracy of the information.

This page will be updated regularly.


  1. World Health Organization (WHO). Media Centre Hepatitis C Fact sheet. July 2018. Available at: (accessed February 2019).
  2. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021.June 2016. Available at: (accessed February 2019).
  3. World Health Organization (WHO). Hepatitis C in the WHO European Region FACT SHEET. July 2018. Available at: (accessed February 2019).
  4. World Health Organization (WHO). Combating hepatitis b and c to reach elimination by 2030. May 2016. Available at: (accessed February 2019).
  5. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151–210.
  6. Solbach P and Wedemeyer H. The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Viszeralmedizin 2015;31:290–6.
  7. Olafsson S, et al. Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med 2018;283:500–7.
  8. Turnes J, et al. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig 2017;109:809–17.
  9. Carrat F, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019. doi:
  10. Duberg S-F, et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol 2015;50:233–44.
  11. The POLARIS Observatory. Available at: (accessed February 2019).

LID/IHQ/18-12//1048h(1) Date of preparation August 2019